Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Tatnic who wrote (6406)	4/12/1999 11:40:00 PM
From: Linda Kaplan	Respond to of 7041

Your read of the TA has been exactly correct, so if you think it's going to 12 before it goes up, I am happy to hear it. The fundamentals are a little more complicated, I think. The problem with MUSE is the delivery system. That product works but given that Viagra works, too, the delivery system will win the race. The main thing for sales is that there be a product that works, of course, and since Vasomax doesn't seem to work, it would have a poor chance of getting sales. Given more than one product that works, delivery system matters, but people will not buy a product twice if it doesn't work for them. I think that's why Vasomax initial sales in Mexico seemed good. The channels were filled on the expectation it would work. But there were no repeat sales because Viagra worked and Vasomax did not. Linda